Vor Biopharma Inc. Investment Income, Interest
Vor Biopharma Inc. (VOR) reported Investment Income, Interest of $4.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-11
- Vor Biopharma Inc. investment income, interest for the quarter ending 2026-06-30 was $4.34M, a 708.75% increase year-over-year.
- Vor Biopharma Inc. investment income, interest for the quarter ending 2026-03-31 was $3.94M, a 388.82% increase year-over-year.
- Vor Biopharma Inc. investment income, interest for the quarter ending 2025-12-31 was $2.79M, a 366.61% increase year-over-year.
- Vor Biopharma Inc. investment income, interest for the quarter ending 2025-09-30 was $1.73M, a 81.45% increase year-over-year.
- Vor Biopharma Inc. investment income, interest for fiscal 2025 was $5.87M, a 37.39% increase from fiscal 2024.
- Vor Biopharma Inc. investment income, interest for fiscal 2024 was $4.27M, a 47.74% decline from fiscal 2023.
- Vor Biopharma Inc. investment income, interest for fiscal 2023 was $8.17M, a 517.30% increase from fiscal 2022.
- Vor Biopharma Inc. investment income, interest for fiscal 2022 was $1.32M, a 1012.61% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.34M 10-Q · filed 2026-08-11 | $8.28M 10-Q · filed 2026-08-11 | $11.07M derived: sum of 3 quarters · filed 2026-08-11 | $12.80M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $3.94M 10-Q · filed 2026-05-13 | $6.73M derived: sum of 2 quarters · filed 2026-05-13 | $8.46M derived: sum of 3 quarters · filed 2026-05-13 | $9.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $4.53M derived: sum of 2 quarters · filed 2026-03-30 | $5.06M derived: sum of 3 quarters · filed 2026-08-11 | $5.87M 10-K · filed 2026-03-30 |
| 2025-09-30 | $1.73M 10-Q · filed 2025-11-13 | $2.27M derived: sum of 2 quarters · filed 2026-08-11 | $3.07M 10-Q · filed 2025-11-13 | $3.67M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $537.00K 10-Q · filed 2026-08-11 | $1.34M 10-Q · filed 2026-08-11 | $1.94M derived: sum of 3 quarters · filed 2026-08-11 | $2.90M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $805.00K 10-Q · filed 2026-05-13 | $1.40M derived: sum of 2 quarters · filed 2026-05-13 | $2.36M derived: sum of 3 quarters · filed 2026-05-13 | $3.55M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $599.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.55M derived: sum of 2 quarters · filed 2026-03-30 | $2.75M derived: sum of 3 quarters · filed 2026-03-30 | $4.27M 10-K · filed 2026-03-30 |
| 2024-09-30 | $954.00K 10-Q · filed 2025-11-13 | $2.15M derived: sum of 2 quarters · filed 2025-11-13 | $3.67M 10-Q · filed 2025-11-13 | $5.54M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.20M 10-Q · filed 2025-08-12 | $2.72M 10-Q · filed 2025-08-12 | $4.58M derived: sum of 3 quarters · filed 2025-08-12 | $6.71M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.52M 10-Q · filed 2025-05-14 | $3.38M derived: sum of 2 quarters · filed 2025-05-14 | $5.51M derived: sum of 3 quarters · filed 2025-05-14 | $7.71M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $3.99M derived: sum of 2 quarters · filed 2025-03-20 | $6.18M derived: sum of 3 quarters · filed 2025-03-20 | $8.17M 10-K · filed 2025-03-20 |
| 2023-09-30 | $2.13M 10-Q · filed 2024-11-07 | $4.32M derived: sum of 2 quarters · filed 2024-11-07 | $6.31M 10-Q · filed 2024-11-07 | $7.13M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $2.19M 10-Q · filed 2024-08-08 | $4.18M 10-Q · filed 2024-08-08 | $5.00M derived: sum of 3 quarters · filed 2024-08-08 | $5.31M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.99M 10-Q · filed 2024-05-09 | $2.80M derived: sum of 2 quarters · filed 2024-05-09 | $3.12M derived: sum of 3 quarters · filed 2024-05-09 | $3.25M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $815.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $1.13M derived: sum of 2 quarters · filed 2024-03-20 | $1.26M derived: sum of 3 quarters · filed 2024-03-20 | $1.32M 10-K · filed 2024-03-20 |
| 2022-09-30 | $313.00K 10-Q · filed 2023-11-07 | $446.00K derived: sum of 2 quarters · filed 2023-11-07 | $509.00K 10-Q · filed 2023-11-07 | $563.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $133.00K 10-Q · filed 2023-08-10 | $196.00K 10-Q · filed 2023-08-10 | $250.00K derived: sum of 3 quarters · filed 2023-08-10 | $298.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $63.00K 10-Q · filed 2023-05-11 | $117.00K derived: sum of 2 quarters · filed 2023-05-11 | $165.00K derived: sum of 3 quarters · filed 2023-05-11 | $175.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $102.00K derived: sum of 2 quarters · filed 2023-03-23 | $112.00K derived: sum of 3 quarters · filed 2023-03-23 | $119.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $48.00K 10-Q · filed 2022-11-10 | $58.00K derived: sum of 2 quarters · filed 2022-11-10 | $65.00K 10-Q · filed 2022-11-10 | $65.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $10.00K 10-Q · filed 2022-08-11 | $17.00K 10-Q · filed 2022-08-11 | $17.00K derived: sum of 3 quarters · filed 2022-08-11 | $17.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $7.00K 10-Q · filed 2022-05-12 | $7.00K derived: sum of 2 quarters · filed 2022-05-12 | $7.00K derived: sum of 3 quarters · filed 2022-05-12 | $7.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $0.00 derived: sum of 2 quarters · filed 2022-03-14 | $0.00 derived: sum of 3 quarters · filed 2022-03-14 | $29.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $29.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $29.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $29.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |